Gilead and Merck Announce Phase 2 Data Showing a Treatment …
Oct 19, 2024 · A Phase 2 study showed that switching to islatravir and lenacapavir, an investigational combination, maintained viral suppression in adults on Biktarvy at Week 48. The novel regimen is advancing to Phase 3 and has the potential to …
Gilead Sciences, Inc. - Gilead’s Phase 2 EVOKE-02 Study of …
Sep 10, 2023 · “The EVOKE-02 trial is the first data presented from several Gilead studies dedicated to exploring Trodelvy’s potential in lung cancer,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology.
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
Sep 12, 2024 · Gilead announced the results of a second pivotal Phase 3 trial showing that lenacapavir reduced HIV infections by 96% compared to background HIV incidence and was superior to Truvada. The company plans to file for regulatory approval of lenacapavir for PrEP in 2025 and to make it available worldwide.
Virology, Inflammation, & Oncology Pipeline | Gilead
Nov 6, 2024 · Explore Gilead's pipeline of investigational compounds for HIV, hepatitis B, hepatitis C, emerging viruses, cancer and inflammation. See the program count, trial phase, therapeutic area and potential opt-in programs for each compound.
"Sons of Anarchy" Gilead (TV Episode 2009) - IMDb
Oct 20, 2009 · Gilead: Directed by Gwyneth Horder-Payton. With Charlie Hunnam, Katey Sagal, Mark Boone Junior, Kim Coates. The club must make new alliances in prison to survive.
Gilead Sciences, Inc. - Gilead and Arcus Announce Anti-TIGIT ...
Jun 1, 2024 · Gilead Sciences and Arcus Biosciences announce positive results from a Phase 2 study of domvanalimab plus zimberelimab and chemotherapy for gastric, gastroesophageal junction or esophageal adenocarcinoma. The combination achieved one-year median progression-free survival and objective response rates exceeding historical benchmarks.
Gilead Presents Additional Efficacy, Safety and Demographic Data …
Oct 7, 2024 · FOSTER CITY, Calif., October 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the...
Final Results From the Randomized Phase III ASCENT Clinical Trial …
Feb 29, 2024 · Sacituzumab govitecan (SG), a first-in-class anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over single-agent chemotherapy (treatment of physician's choice [TPC]) in patients with metastatic triple-negative breast cancer (mTNBC) in the international, multicenter, phase III ASCENT study.
Gilead Sciences, Inc. - Financials - SEC Filings
At Gilead, we promise to treat your data with respect. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
Gilead’s Innovative HIV Treatment Research Pipeline Aims to …
Mar 5, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.